CEOP/IVE/GDP alternating regimen compared with CEOP as the first-line therapy for newly diagnosed patients with peripheral T cell lymphoma: results from a phase 2, multicenter, randomized, controlled…

Overview of attention for article published in Genome Medicine, April 2020

Altmetric Badge

About this Attention Score

Good Attention Score compared to outputs of the same age (65th percentile)
Average Attention Score compared to outputs of the same age and source

Mentioned by

twitter: 2 X users

patent: 1 patent

Citations

dimensions_citation: 7 Dimensions

Readers on

mendeley: 31 Mendeley

Summary X Patents Dimensions citations

So far, Altmetric has seen 1 patent that references this research output.

NOVEL BIOMARKER FOR PREDICTING PROGNOSIS OF PERIPHERAL T CELL LYMPHOMA, AND USE THEREOF

Application WO-2023054851-A1

World Intellectual Property Organisation (WIPO)

This page shows the most recent patents that mention this research output.

Click here to find out how to access more activity.